| 000 | 01693 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250515223203.0 | ||
| 264 | 0 | _c20100614 | |
| 008 | 201006s 0 0 eng d | ||
| 022 | _a1529-0131 | ||
| 024 | 7 |
_a10.1002/art.27383 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSong, I-H | |
| 245 | 0 | 0 |
_aDifferent response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. _h[electronic resource] |
| 260 |
_bArthritis and rheumatism _cMay 2010 |
||
| 300 |
_a1290-7 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aAntigens, CD20 _xmetabolism |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aB-Lymphocytes _xcytology |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aSpondylitis, Ankylosing _xdrug therapy |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 700 | 1 | _aHeldmann, F | |
| 700 | 1 | _aRudwaleit, M | |
| 700 | 1 | _aListing, J | |
| 700 | 1 | _aAppel, H | |
| 700 | 1 | _aBraun, J | |
| 700 | 1 | _aSieper, J | |
| 773 | 0 |
_tArthritis and rheumatism _gvol. 62 _gno. 5 _gp. 1290-7 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/art.27383 _zAvailable from publisher's website |
| 999 |
_c19816596 _d19816596 |
||